Skip to main content
CSPC Pharmaceutical Group Limited logo

CSPC Pharmaceutical Group Limited — Investor Relations & Filings

Ticker · 1093 ISIN · US12591J1088 LEI · 529900M3XQCW234H8O91 HKEX Manufacturing
Open in API
Filings indexed 1,510 across all filing types
Latest filing 2026-05-22 Regulatory Filings
Country HK Hong Kong
Listing HKEX 1093

About CSPC Pharmaceutical Group Limited

https://www.cspc.com.hk/en/global/home.…

CSPC Pharmaceutical Group Limited is a comprehensive enterprise specializing in the research, development, manufacturing, and sale of pharmaceutical products. The company operates across two main segments: finished drugs and bulk drugs. It emphasizes innovation and new drug development, evidenced by substantial R&D investment, to produce high-quality, effective, and reliable medicines. Its portfolio includes key innovative products such as NBP (soft capsules and injections), Oulaining, and Enxi, which are among its top-selling drugs.

Recent filings

Filing Released Lang Actions
VOLUNTARY ANNOUNCEMENT - USTEKINUMAB INJECTION RECEIVES MARKETING AUTHORISATION FROM NMPA
Regulatory Filings Classification · 82% confidence The document is a voluntary announcement on the Stock Exchange of Hong Kong regarding a pharmaceutical product receiving marketing authorisation from China’s NMPA. It does not contain financial statements, management discussion of results, voting or dividend details, nor is it a statutory report (e.g., annual or interim report). It is a general regulatory/compliance announcement. Therefore, it should be classified as a Regulatory Filing (RNS).
2026-05-22 English
VOLUNTARY ANNOUNCEMENT - BUDESONIDE ENTERIC-COATED CAPSULES OBTAIN DRUG REGISTRATION APPROVAL
Regulatory Filings Classification · 90% confidence The document is a voluntary announcement published on the Hong Kong Stock Exchange platform, providing regulatory information regarding drug registration approval for a pharmaceutical product. It does not contain financial data, board changes, voting results, or details of a formal financial report. It is a general regulatory disclosure and therefore best classified under Regulatory Filings (RNS).
2026-05-21 English
VOLUNTARY ANNOUNCEMENT - HIGHLY SELECTIVE KAT6 INHIBITOR (SYH2095 TABLETS) OBTAINS CLINICAL TRIAL APPROVAL IN CHINA
Regulatory Filings Classification · 85% confidence The document is a voluntary corporate announcement on the HKEX about clinical trial approval for a new drug. It does not present financial statements or detailed investor materials, nor does it relate to board changes, dividends, M&A, or share transactions. It is a general regulatory announcement filed with the exchange, thus falling under the “Regulatory Filings” fallback category (RNS).
2026-05-18 English
DATE OF BOARD MEETING
Regulatory Filings Classification · 90% confidence The document is a notice announcing the date of a Board meeting to approve the company's unaudited first quarterly results. It does not contain any financial figures or constitute the actual quarterly report, nor is it an AGM notice or management change. It simply notifies investors of an upcoming board meeting, which is a miscellaneous regulatory announcement. Therefore it falls under the general ‘Regulatory Filings’ category (RNS).
2026-05-14 English
SHARE OPTION SCHEME
Governance Information Classification · 85% confidence The document is the full text of the CSPC Pharmaceutical Group Limited share option scheme, including definitions, administration rules, vesting schedules and conditions adopted at the AGM. It is not announcing a specific capital transaction or announcing voting results, nor is it a standalone notice of share issuance or proxy solicitation. Instead, it sets out internal governance rules and policies concerning the Company’s equity incentive plan. Therefore, it best fits the Governance Information category (CGR).
2026-05-13 English
VOLUNTARY ANNOUNCEMENT - SYS6010 GRANTED ANOTHER BREAKTHROUGH THERAPY DESIGNATION IN CHINA FOR THE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC ESOPHAGEAL SQUAMOUS CELL CARCINOMA
Regulatory Filings Classification · 85% confidence The document is a voluntary corporate announcement to the stock exchange regarding a product’s Breakthrough Therapy Designation by China’s NMPA. It contains no financial statements or management changes, and it is not an earnings release or formal report. This type of miscellaneous regulatory announcement falls under the fallback category "Regulatory Filings (RNS)."
2026-05-11 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.